https://www.onclive.com/view/fda-approves-camizestrant-plus-a-cdk4-6-inhibitor-for-emergent-esr1-mutated-hr-her2-advanced-breast-cancer2026-09-04T19:54:17.797Z2026-09-04T19:54:17.797Z https://www.onclive.com/view/brachytherapy-and-minimally-invasive-surgical-techniques-signal-the-future-of-brain-cancer-management2026-09-04T19:44:38.695Z2026-09-04T19:44:38.695Z https://www.onclive.com/view/herbert-lepor-md-on-focal-cryotherapy-1-000-procedures-and-andre-de-shields2026-09-04T19:00:00Z2026-09-04T19:00:00Z https://www.onclive.com/view/balazs-halmos-md-answers-the-internet-s-questions-about-lung-cancer2026-09-04T18:13:44.570Z2026-09-04T18:13:44.570Z https://www.onclive.com/view/joshua-richter-md-answers-doctor-s-questions-about-multiple-myeloma2026-09-04T18:12:01.506Z2026-09-04T18:12:01.506Z https://www.onclive.com/view/biomarker-testing-and-access-barriers-in-egfr-mutated-nsclc2026-09-04T18:10:06.726Z2026-09-04T18:10:06.726Z https://www.onclive.com/view/maurie-markman-md-answers-clinical-questions-about-ai-and-gynecologic-oncology2026-09-04T18:08:45.131Z2026-09-04T18:08:45.131Z https://www.onclive.com/view/multidisciplinary-toxicity-management-in-egfr-mutated-nsclc2026-09-04T18:04:09.050Z2026-09-04T18:04:09.050Z https://www.onclive.com/view/adverse-events-prompting-dose-modification-in-egfr-mutated-nsclc2026-09-04T17:56:41.867Z2026-09-04T17:56:41.867Z https://www.onclive.com/view/emerging-antibody-drug-conjugate-combinations-in-egfr-mutated-nsclc2026-09-04T17:51:23.098Z2026-09-04T17:51:23.098Z https://www.onclive.com/view/second-line-sequencing-after-frontline-progression-in-egfr-mutated-nsclc2026-09-04T17:49:18.466Z2026-09-04T17:49:18.466Z https://www.onclive.com/view/selecting-frontline-therapy-for-high-risk-egfr-mutated-nsclc2026-09-04T17:44:42.610Z2026-09-04T17:44:42.610Z https://www.onclive.com/view/tp53-co-mutations-and-prognosis-in-egfr-mutated-nsclc2026-09-04T17:40:34.751Z2026-09-04T17:40:34.751Z https://www.onclive.com/view/closing-reflections-and-key-takeaways2026-09-04T17:37:47.596Z2026-09-04T17:37:47.596Z https://www.onclive.com/view/met-directed-resistance-in-egfr-mutant-nsclc-testing-treatment-matching-and-toxicity-management2026-09-04T17:36:24.239Z2026-09-04T17:36:24.239Z https://www.onclive.com/view/second-line-regimen-choice-and-re-biopsy-realities-in-egfr-mutant-nsclc-after-osimertinib2026-09-04T17:34:25.820Z2026-09-04T17:34:25.820Z https://www.onclive.com/view/datopotamab-druxtecan-and-adc-toxicity-management-in-egfr-mutant-nsclc2026-09-04T17:33:05.132Z2026-09-04T17:33:05.132Z https://www.onclive.com/view/managing-progression-in-egfr-mutant-nsclc-re-biopsy-small-cell-transformation-and-cns-surveillance2026-09-04T17:31:35.949Z2026-09-04T17:31:35.949Z https://www.onclive.com/view/sequencing-strategy-in-egfr-mutant-nsclc-how-frontline-choices-shape-later-options2026-09-04T17:29:48.074Z2026-09-04T17:29:48.074Z https://www.onclive.com/view/practical-management-in-egfr-mutant-nsclc-infusion-logistics-skin-toxicity-and-quality-of-life2026-09-04T17:28:24.490Z2026-09-04T17:28:24.490Z https://www.onclive.com/view/introduction-and-frontline-regimen-selection-in-egfr-mutant-nsclc2026-09-04T17:21:24.896Z2026-09-04T17:21:24.896Z https://www.onclive.com/view/new-cancer-campus-begins-to-rise-in-vineyard2026-09-04T16:00:00Z2026-09-04T16:00:00Z https://www.onclive.com/view/current-approaches-and-future-directions-for-early-stage-tnbc2026-09-04T14:00:00Z2026-09-04T14:00:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-9-4-2026-did-you-miss-key-mpn-myeloma-and-lung-cancer-updates-2026-09-04T13:57:58.722Z2026-09-04T13:57:58.722Z https://www.onclive.com/view/novel-analysis-reveals-millions-of-life-years-saved-by-blood-cancer-treatments2026-09-04T13:55:00Z2026-09-04T13:55:00Z https://www.onclive.com/view/sonrotoclax-approval-generates-new-options-and-possibilities-for-r-r-mcl2026-09-04T13:00:00Z2026-09-04T13:00:00Z https://www.onclive.com/view/supportive-care-and-crs-mitigation-with-bispecific-antibodies-in-multiple-myeloma2026-09-04T12:05:00Z2026-09-04T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-optimizing-early-use-of-car-t-cell-therapy2026-09-04T12:05:00Z2026-09-04T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-distinguishing-car-t-eligibility-from-transplant-eligibility2026-09-04T12:00:00Z2026-09-04T12:00:00Z https://www.onclive.com/view/early-relapse-treatment-and-sequencing-in-multiple-myeloma2026-09-04T12:00:00Z2026-09-04T12:00:00Z https://www.onclive.com/view/daraxonrasib-yields-durable-responses-in-previously-treated-ras-mutant-nsclc2026-09-03T21:00:00Z2026-09-03T21:00:00Z https://www.onclive.com/view/ivonescimab-meets-os-end-point-vs-pembrolizumab-in-first-line-pd-l1-nsclc2026-09-03T16:55:54.838Z2026-09-03T16:55:54.838Z https://www.onclive.com/view/alcohol-linked-cancer-s-toll-extends-far-beyond-the-liver-with-deaths-rising-across-age-groups2026-09-03T16:00:01.910Z2026-09-03T16:00:01.910Z https://www.onclive.com/view/novel-therapies-are-poised-to-answer-questions-and-reinvigorate-hematologic-oncology-at-soho-20262026-09-03T15:07:50.347Z2026-09-03T15:07:50.347Z https://www.onclive.com/view/etentamig-meets-dual-primary-end-points-in-triple-class-exposed-r-r-myeloma2026-09-03T14:58:19.866Z2026-09-03T14:58:19.866Z https://www.onclive.com/view/a-new-player-in-the-adjuvant-setting-glp-1-agonists-and-the-fight-against-breast-cancer-metastasis2026-09-03T14:00:00Z2026-09-03T14:00:00Z https://www.onclive.com/view/future-directions-beyond-osimertinib-in-egfr-mutant-nsclc2026-09-03T12:05:00Z2026-09-03T12:05:00Z https://www.onclive.com/view/comorbidities-and-risk-benefit-discussions-in-the-adjuvant-setting2026-09-03T12:05:00Z2026-09-03T12:05:00Z https://www.onclive.com/view/aml-research-centers-around-the-optimization-of-available-combinations2026-09-03T12:00:00Z2026-09-03T12:00:00Z https://www.onclive.com/view/case-presentation-a-68-year-old-man-with-resected-high-risk-cutaneous-squamous-cell-carcinoma2026-09-03T12:00:00Z2026-09-03T12:00:00Z https://www.onclive.com/view/addressing-access-barriers-and-financial-toxicity-in-egfr-mutant-nsclc2026-09-03T12:00:00Z2026-09-03T12:00:00Z https://www.onclive.com/view/tamp-mediated-gemcitabine-lowers-systemic-exposure-vs-iv-delivery-in-locally-advanced-pancreatic-cancer2026-09-02T20:20:00Z2026-09-02T20:20:00Z https://www.onclive.com/view/dr-sykes-on-the-rationale-for-exploring-mavorixafor-in-chronic-neutropenia2026-09-02T17:36:45.509Z2026-09-02T17:36:45.509Z https://www.onclive.com/view/giuliani-family-announces-remarkable-commitment-of-27-8-million-to-dana-farber-cancer-institute-to-advance-progress-in-multiple-myeloma-research2026-09-02T16:00:00Z2026-09-02T16:00:00Z https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-jbs-003-for-radiation-de-escalation-in-hpv-oropharyngeal-cancer2026-09-02T14:48:14.145Z2026-09-02T14:48:14.145Z https://www.onclive.com/view/august-roundup-of-fda-approvals-in-oncology-daraxonrasib-highlights-5-decisions-to-know2026-09-02T13:00:00Z2026-09-02T13:00:00Z https://www.onclive.com/view/real-world-tirabrutinib-use-in-primary-cns-lymphoma2026-09-02T12:20:00Z2026-09-02T12:20:00Z https://www.onclive.com/view/tirabrutinib-in-relapsed-refractory-primary-cns-lymphoma2026-09-02T12:15:00Z2026-09-02T12:15:00Z https://www.onclive.com/view/btk-inhibitors-in-relapsed-refractory-primary-cns-lymphoma2026-09-02T12:10:00Z2026-09-02T12:10:00Z https://www.onclive.com/view/managing-patients-already-receiving-sunitinib-in-second-line-gist2026-09-02T12:05:00Z2026-09-02T12:05:00Z https://www.onclive.com/view/new-biomarker-driven-regimens-prompt-debate-over-treatment-intensification-in-advanced-prostate-cancer2026-09-02T12:00:00Z2026-09-02T12:00:00Z https://www.onclive.com/view/regulatory-outlook-and-later-line-sequencing-in-kit-mutant-gist2026-09-02T12:00:00Z2026-09-02T12:00:00Z https://www.onclive.com/view/tp53-status-treatment-toxicity-burden-guide-sequencing-egfr-mutated-nsclc2026-09-01T22:00:00Z2026-09-01T22:00:00Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt027-for-recurrent-glioblastoma2026-09-01T20:48:56.574Z2026-09-01T20:48:56.574Z https://www.onclive.com/view/a-breast-radiologist-breaks-down-breast-cancer-screening-guidelines-with-sara-nunnery-md-msci-and-dana-bonaminio-md2026-09-01T20:25:03.949Z2026-09-01T20:25:03.949Z https://www.onclive.com/view/dr-gerds-on-how-to-approach-jak-inhibitor-selection-in-myelofibrosis2026-09-01T19:20:01.564Z2026-09-01T19:20:01.564Z https://www.onclive.com/view/european-commission-approves-t-dxd-plus-pertuzumab-for-first-line-her2-metastatic-breast-cancer2026-09-01T16:25:00Z2026-09-01T16:25:00Z https://www.onclive.com/view/mayo-clinic-researcher-leads-lancet-commission-reports-on-life-during-and-after-blood-cancer-treatment2026-09-01T16:00:00.000Z2026-09-01T16:00:00Z https://www.onclive.com/view/dr-huffman-on-the-mechanism-of-action-of-incb161734-in-kras-g12d-mutated-metastatic-pancreatic-cancer2026-09-01T14:46:26.179Z2026-09-01T14:46:26.179Z https://www.onclive.com/view/comprehensive-rna-based-testing-and-selective-next-generation-tkis-are-reshaping-frontline-ros1-nsclc-care2026-09-01T14:00:00Z2026-09-01T14:00:00Z https://www.onclive.com/view/novel-precision-surgery-processes-pave-the-way-for-sarcoma-management-shifts2026-09-01T13:00:00Z2026-09-01T13:00:00Z https://www.onclive.com/view/car-t-cell-therapy-in-older-adults-with-large-b-cell-lymphoma2026-09-01T12:05:00Z2026-09-01T12:05:00Z https://www.onclive.com/view/cytopenia-status-helps-drive-jak-inhibitor-selection-in-myelofibrosis2026-09-01T12:00:00Z2026-09-01T12:00:00Z https://www.onclive.com/view/interpreting-real-world-evidence-in-large-b-cell-lymphoma2026-09-01T12:00:00Z2026-09-01T12:00:00Z https://www.onclive.com/view/dr-kantarjian-on-long-term-data-for-dose-optimized-ponatinib-in-cml2026-08-31T21:48:22.980Z2026-08-31T21:48:22.980Z https://www.onclive.com/view/mapkeeper-301-aims-to-confirm-the-efficacy-of-atebimetinib-plus-chemotherapy-in-first-line-metastatic-pancreatic-cancer2026-08-31T21:36:37.527Z2026-08-31T21:36:37.527Z https://www.onclive.com/view/aspen-09-03-trial-aims-to-build-the-case-for-evorpacept-in-post-t-dxd-her2-breast-cancer2026-08-31T21:35:10.108Z2026-08-31T21:35:10.108Z https://www.onclive.com/view/unmet-needs-in-allogeneic-transplant-and-precision-t-data-discussion2026-08-31T18:50:00Z2026-08-31T18:50:00Z https://www.onclive.com/view/non-small-cell-lung-cancer-2026-update2026-08-31T17:30:00Z2026-08-31T17:30:00Z https://www.onclive.com/view/ttfields-add-a-new-dimension-to-the-changing-pancreatic-cancer-treatment-paradigm2026-08-31T17:00:00Z2026-08-31T17:00:00Z https://www.onclive.com/view/this-is-how-to-treat-cancer-with-teacher-cells-and-tumor-pieces2026-08-31T16:00:00Z2026-08-31T16:00:00Z https://www.onclive.com/view/zanidatamab-plus-chemotherapy-improves-os-at-second-interim-analysis-of-herizon-gea-01-in-first-line-her2-gea2026-08-31T15:30:00Z2026-08-31T15:30:00Z https://www.onclive.com/view/dr-mesa-on-the-fda-approval-of-ropeginterferon-alfa-2b-for-essential-thrombocythemia2026-08-31T15:21:42.345Z2026-08-31T15:21:42.345Z https://www.onclive.com/view/savolitinib-plus-osimertinib-improves-first-line-pfs-in-met-overexpressing-egfr-mutated-nsclc2026-08-31T14:19:46.352Z2026-08-31T14:19:46.352Z https://www.onclive.com/view/fda-receives-snda-for-selinexor-plus-ruxolitinib-in-jak-inhibitor-naive-myelofibrosis2026-08-31T14:11:11.376Z2026-08-31T14:11:11.376Z https://www.onclive.com/view/biology-and-btk-rationale-in-primary-cns-lymphoma2026-08-31T13:00:09.231Z2026-08-31T13:00:09.231Z https://www.onclive.com/view/introducing-btk-inhibition-in-primary-cns-lymphoma2026-08-31T12:56:53.728Z2026-08-31T12:56:53.728Z https://www.onclive.com/view/endoscopic-and-biomarker-workup-of-post-car-t-diarrhea2026-08-31T12:05:00Z2026-08-31T12:05:00Z https://www.onclive.com/view/sequencing-car-t-cell-therapy-in-multiple-myeloma2026-08-31T12:05:00Z2026-08-31T12:05:00Z https://www.onclive.com/view/fda-approves-ropeginterferon-alfa-2b-for-essential-thrombocythemia2026-08-31T12:00:00Z2026-08-31T12:00:00Z https://www.onclive.com/view/treatment-sequencing-in-early-relapsed-refractory-multiple-myeloma2026-08-31T12:00:00Z2026-08-31T12:00:00Z https://www.onclive.com/view/recognizing-immune-effector-cell-associated-enterocolitis-after-car-t2026-08-31T12:00:00Z2026-08-31T12:00:00Z https://www.onclive.com/view/focal-therapy-for-prostate-cancer-a-historical-perspective-of-clinical-trials-and-looking-forward2026-08-31T12:00:00Z2026-08-31T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-8-232026-08-30T12:00:00Z2026-08-30T12:00:00Z https://www.onclive.com/view/destiny-breast05-safety-analysis-clarifies-ild-and-radiation-risks-with-t-dxd-in-her2-breast-cancer2026-08-30T10:00:00Z2026-08-30T10:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-8-232026-08-29T12:00:00Z2026-08-29T12:00:00Z https://www.onclive.com/view/tdi01-elicits-responses-with-manageable-safety-in-moderate-to-severe-cgvhd2026-08-29T10:00:00Z2026-08-29T10:00:00Z https://www.onclive.com/view/fda-approves-rusfertide-for-polycythemia-vera2026-08-28T22:47:27.162Z2026-08-28T22:47:27.162Z https://www.onclive.com/view/fda-approval-insights-integrating-rp1-plus-nivolumab-into-post-pd-1-melanoma-practice-with-michael-k-wong-md-phd-frpc2026-08-28T18:30:00Z2026-08-28T18:30:00Z https://www.onclive.com/view/belzutifan-plus-lenvatinib-yields-comparable-hrqol-to-cabozantinib-in-post-pd--l-1-rcc2026-08-28T18:00:00Z2026-08-28T18:00:00Z https://www.onclive.com/view/dawn-303-trial-set-to-advance-incb161734-in-first-line-kras-g12d-mutated-metastatic-pancreatic-cancer2026-08-28T17:00:00Z2026-08-28T17:00:00Z https://www.onclive.com/view/immunotherapy-decision-making-in-cscc-sits-at-the-intersection-of-efficacy-and-comorbidity-with-eric-d-whitman-md-and-francis-paul-worden-md2026-08-28T16:36:42.226Z2026-08-28T16:36:42.226Z https://www.onclive.com/view/dana-farber-cancer-institute-announces-35-million-gift-from-richard-k-and-nancy-k-lubin-to-support-the-future-of-cancer-care2026-08-28T16:00:00Z2026-08-28T16:00:00Z https://www.onclive.com/view/ponatinib-dose-adjustments-preserve-potency-and-improve-toxicity-in-cml2026-08-28T15:02:09.906Z2026-08-28T15:02:09.906Z https://www.onclive.com/view/onclive-weekly-news-quiz-8-28-2026-pancreatic-gastric-breast-biliary-tract-updates2026-08-28T14:00:00Z2026-08-28T14:00:00Z https://www.onclive.com/view/china-s-nmpa-approves-fanregratinib-for-pretreated-fgfr2-intrahepatic-cholangiocarcinoma2026-08-28T12:53:11.672Z2026-08-28T12:53:11.672Z https://www.onclive.com/view/individualized-treatment-and-sequencing-in-multiple-myeloma2026-08-28T12:05:00Z2026-08-28T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-multidisciplinary-care-and-caregiver-support2026-08-28T12:05:00Z2026-08-28T12:05:00Z https://www.onclive.com/view/multidisciplinary-ca-lems-care-models-in-small-cell-lung-cancer-workflows-treatment-outcomes-evidence-gaps-and-closing-pearls2026-08-28T12:05:00Z2026-08-28T12:05:00Z https://www.onclive.com/view/treating-ca-lems-in-small-cell-lung-cancer-amifampridine-immunomodulatory-therapy-and-ici-safety-considerations2026-08-28T12:00:00Z2026-08-28T12:00:00Z